Lung Diseases: all 3,319 studies

Page 7 of 34. Open to participants first (355), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02130635Phase 2Results posted
• Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD PatientsCompletedNCT02125734Phase 4Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2CompletedNCT02119286Phase 3Results posted
• A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02109172Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105974Phase 3Results posted
• Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105961Phase 3Results posted
• Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02105948Phase 3Results posted
• Comparative Effectiveness of a Peer-led O2 Infoline for Patients and CaregiversCompletedNCT02098369Phase 4Results posted
• Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary EventsCompletedNCT02096731Results posted
• To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of AirwaysCompletedNCT02085161Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02077465Phase 1Results posted
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.CompletedNCT02075541Phase 2Results posted
• Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)CompletedNCT02070757Phase 3Results posted
• Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPDCompletedNCT02059434Phase 1Results posted
• A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02040792Phase 2Results posted
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATCompletedNCT02036970Phase 2Results posted
• Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02036294Not applicableResults posted
• Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different InhalersCompletedNCT02030535Phase 2Results posted
• Uncontrolled Lower Respiratory Symptoms in the WTC Survivor ProgramCompletedNCT02024204Not applicableResults posted
• The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung DiseaseCompletedNCT02019641Not applicableResults posted
• A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02014480Phase 3Results posted
• Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)CompletedNCT02006732Phase 3Results posted
• Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.CompletedNCT01996319Phase 3Results posted
• A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01978145Phase 3Results posted
• Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD PatientsCompletedNCT01969721Phase 3Results posted
• Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)CompletedNCT01964352Phase 3Results posted
• BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic BronchitisCompletedNCT01958008Phase 1Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01957163Phase 3Results posted
• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01957150Phase 4Results posted
• Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung DiseaseCompletedNCT01948518Not applicableResults posted
• Ipratropium Bromide in Peri-Operative COPDCompletedNCT01943552Phase 4Results posted
• Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01937390Results posted
• Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD PatientsCompletedNCT01933984Not applicableResults posted
• Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)CompletedNCT01933334Phase 2Results posted
• Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01922271Phase 4Results posted
• Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPDCompletedNCT01917331Phase 3Results posted
• Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01908140Phase 3Results posted
• Physical Training and Heart Rate Variability in COPDCompletedNCT01889563Not applicableResults posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01879410Phase 3Results posted
• DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01868009Phase 3Results posted
• Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic SurgeryCompletedNCT01867658Not applicableResults posted
• Tadalafil for Pulmonary Hypertension Due to Chronic Lung DiseaseCompletedNCT01862536Phase 2Results posted
• Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)CompletedNCT01857323Phase 3Results posted
• Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)CompletedNCT01854645Phase 3Results posted
• Differentiating the Effects of Substance P and Beta-endorphinCompletedNCT01854177Not applicableResults posted
• COPD Assessment and Management Bundle Versus Usual CareCompletedNCT01833026Not applicableResults posted
• Acute Effects of a Flutter Device in COPDCompletedNCT01832961Not applicableResults posted
• A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01822899Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01817764Phase 3Results posted
• Preference Tiotropium Respimat Study in COPDCompletedNCT01810692Results posted
• Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary DiseaseCompletedNCT01809262Phase 2Results posted
• A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting BronchodilatorCompletedNCT01794780Phase 4Results posted
• Effect of Symbicort ® on GR in Sputum in COPDCompletedNCT01787097Phase 4Results posted
• The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPDCompletedNCT01777334Phase 3Results posted
• Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPDCompletedNCT01745848Phase 4Results posted
• Doxycycline for COPD in HIV-Infected PatientsCompletedNCT01744093Not applicableResults posted
• Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD PatientsCompletedNCT01727024Phase 4Results posted
• Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcgCompletedNCT01716520Phase 3Results posted
• NVA237 BID Versus Placebo Twelve-week Efficacy StudyCompletedNCT01715298Phase 3Results posted
• Effects of Symbicort on the Ventilatory KinematicsTerminatedNCT01712854Phase 4Results posted
• A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149CompletedNCT01709903Phase 3Results posted
• NVA237 Versus Placebo 12-week Efficacy StudyCompletedNCT01709864Phase 3Results posted
• Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01708278Phase 1Results posted
• A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) PatientsTerminatedNCT01708057Phase 2Results posted
• A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01706328Phase 3Results posted
• 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01704404Phase 2Results posted
• A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.CompletedNCT01703845Phase 1Results posted
• Long-term Safety Study for GSK573719 in JapaneseCompletedNCT01702363Phase 3Results posted
• Long Term Safety Study of NVA237 vs QAB149 in COPD PatientsCompletedNCT01697696Phase 3Results posted
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®CompletedNCT01696058Phase 3Results posted
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®CompletedNCT01694771Phase 3Results posted
• A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and IpratropiumCompletedNCT01691482Phase 4Results posted
• Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic TreatmentCompletedNCT01679314Not applicableResults posted
• Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen ConcentratorCompletedNCT01679301Not applicableResults posted
• BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With CachexiaCompletedNCT01669174Phase 2Results posted
• Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1CompletedNCT01663987Phase 4Results posted
• Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2CompletedNCT01662986Phase 4Results posted
• A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mgCompletedNCT01658020Phase 3Results posted
• Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) TestCompletedNCT01644734Phase 4Results posted
• A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPDCompletedNCT01636713Phase 3Results posted
• Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways DiseaseCompletedNCT01634620Results posted
• Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01630200Phase 4Results posted
• Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular DiseaseCompletedNCT01627327Phase 3Results posted
• Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant SuitabilityCompletedNCT01615484Not applicableResults posted
• Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01613326Phase 3Results posted
• Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow LimitationCompletedNCT01610037Phase 3Results posted
• ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01607398Phase 4Results posted
• Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01604278Phase 3Results posted
• Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01587079Phase 2Results posted
• Mindfulness Mediation Intervention in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01577329Not applicableResults posted
• Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01572792Phase 3Results posted
• Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01566604Phase 3Results posted
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung DiseaseTerminatedNCT01559129Phase 2Results posted
• Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary DiseaseCompletedNCT01559116Phase 3Results posted
• Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)CompletedNCT01555138Phase 4Results posted
• Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung DiseaseTerminatedNCT01554488Phase 4Results posted
• Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551888Phase 2Results posted
• A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551758Phase 3Results posted
• Japan Long-term Safety for Tiotropium Plus OlodaterolCompletedNCT01536262Phase 3Results posted
• Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.CompletedNCT01533935Phase 3Results posted

← Lung Diseases overview